
Pediatric intoxication inducing after dental pain management OTC Benzocaine product

Dr. Muhi. N. Salman*

**M.Sc Toxicology Baghdad College of medical sciences, baghdad. Iraq*

*Corresponding Email: *drdamuk12@gmail.com*

Received: 28 April 2021

Accepted: 22 July 2021

Published: 18 August 2021

Abstract; Background; Methemoglobinemia is a rare disorder of the blood in which there is an increase in the proportion of hemoglobin present in the oxidized form (methemoglobin). It may be inherited, due either to a deficiency of methemoglobin reductase or to a structural abnormality of hemoglobin, or it may be acquired, usually secondary to exposure to drugs or chemicals that oxidize hemoglobin. Administration of some local anesthetics such as benzocaine at large doses may lead to an acute effect of risk Methemoglobinemia..

Presentation ; A 6-years-old child was suffering from dyspnea, headache, and grayish in appearance. The patient was self-treating with an over-the-counter topical oral benzocaine.

Treatment; The diagnosis of methemoglobinemia was made in conjunction with consultation with a medical toxicologist and treatment with oxygen and methylene blue as antidote was given 1mg/kg of 1% solution intravenously over 7minutes. The symptoms improved within 30 minutes and child felt markedly better within 1.5 hour.

Conclusion; Methylene blue is the specific antidote, but should be reserved for more severe cases.

1. INTRODUCTION

FDA issued a safety communication¹ warning health professionals and consumers that OTC benzocaine products should not be used in infants and children younger than 2 years and should only be used in adults and children older than 2 years. FDA also urged manufacturers to add warnings to their products' labels about benzocaine's potential to cause methemoglobinemia, a serious condition that changes the transport of oxygen to body tissues.⁽¹⁾ These products carry serious risks and provide little to no benefits for treating oral pain, due to the significant safety risk of methemoglobinemia blue lips and nail beds. Acquired methemoglobinemia is typically caused by oxidative stress and many prescribed medications are strongly associated with inducing methemoglobinemia e.g., Lidocaine , Metoclopramide, Prilocaine, Amyl nitrite, Nitroglycerin, Nitroprusside, sulfamethoxazole [2, 3]. A very common presentation of this cyanotic illness is after a medical procedure, such as endoscopy or bronchoscopy, during which a liberal amount of local anesthetic, such as benzocaine spray or gel is used [2,4,5]. The reported maximum dose before inducing methemoglobinemia would be 15mg per kilogram for a 50 kg person [6

2. CASE PRESENTATION:

A 6-year-old male brought by his mother to the outpatient of private polyclinic suffering from generalized weakness since the previous evening. He also reported dyspnea, headache, and dizziness, which started, and his mother noted his skin to be pale and grayish in appearance. The patient also reported that he had a toothache for several days and was self-treating with an over-the-counter topical medication, Maximum Strength Orajel (benzocaine) (Figure 2). He stated he had been applying the gel three times per day for three days.

Physical examination revealed an alert, mildly distressed, cyanotic-appearing child. His vital signs revealed a temperature of 35 °C, heart rate of 72 beats per minute, blood pressure of 140/60 mmHg, respirations at 18 breaths per minute. The child's skin displayed moderate pallor with perioral cyanosis. Upon initial venous blood draw, his blood had an abnormal chocolate-brown appearance (Figure 1). Laboratory studies revealed arterial blood measured pH, 7.32 (7.35–7.45); total calculated hemoglobin, 16.3 g/dL; oxyhemoglobin, 70.9% (95.0–98.0); carboxyhemoglobin, 0.026% (0.5–1–5); methemoglobin, 28.4%. The diagnosis of



methemoglobinemia was made in conjunction with consultation with a medical toxicologist and treatment with oxygen and methylene blue as antidote was given (1 mg/kg of 1% solution intravenously over 7 minutes), indicated for symptomatic patients or methemoglobin levels greater than 25 to 30%. The symptoms improved within 30 minutes and child felt markedly better within 1-5 hours. The oxyhemoglobin at 94.5% and methemoglobin at 0.9%. After a 6-hour stay of nursing under observation and complete resolution of his signs and symptoms, child was discharged with the instruction to discontinue the use of the OTC Benzocaine's product and seek appropriate dental care.

Figure [1] Chocolate Blood Sample

3. DISCUSSION AND CONCLUSION

Methemoglobinemia is a hemoglobinopathy that can be induced by methemoglobinemia due to the exposure to an oxidizing chemical or drug, leading to the removal of an electron from ferrous hemoglobin (Fe²⁺) to create ferric hemoglobin (Fe³⁺) at a rate that surpasses the endogenous reducing mechanisms, which primarily include the enzymatic activity of cytochrome b5 reductase and nicotinamide adenine dinucleotide (NADH) methemoglobin reductase [7,8]. The clinical manifestation of methemoglobinemia, %MetHgb, symptomatology, and chocolate-brown appearance of blood, metabolic acidosis, and classic presentation of a patient with methemoglobinemia are dyspnea, pallor, grayish skin, cyanosis, and hypoxia were



major assistance fast for the clinical diagnosis for poor facilities of available clinical laboratory in outpatient reception [9,10].The consistency of oral gels contributes to potential overdosing inducing therapeutic error ends up with benzocaine methhemoglobinemia intoxication[11].

4. REFERENCES

1. FDA.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/Pharmacy Today , AUGUST 2018
2. King, N. Menke, and K. Katz, “Toxic hemoglobinopathies in the emergency department,” *EM Critical Care*, vol. 3, no.6, pp. 1–17, 2013, <http://www.slremeducation.org/wp-content/uploads/2015/02/1213-Toxic-Hemoglobinopathies.pdf>.
3. J. Ashurst and M. Wasson, “Methemoglobinemia: a systematic review of the pathophysiology, detection, and treatment,” *Delaware Medical Journal*, vol. 83, no. 7, pp. 203–208, 2011.
4. T. J. Moore, C. S. Walsh, and M. R. Cohen, “Reported adverse event cases of methemoglobinemia associated with benzocaine products,” *Archives of Internal Medicine*, vol. 164, no. 11, pp.1192–1196, 2004.
5. N.-Y. Chung, R. Batra, M. Itzkevitch, D. Boruchov, and M. Baldauf, “Severe methemoglobinemia linked to gel-type topical benzocaine use: a case Report,” *Journal of Emergency Medicine*, [7] vol. 38, no. 5, pp. 601–606, 2010.
6. E. V. Hersh, S. G. Ciancio, A. S. Kuperstein et al., “An evaluation of 10 percent and 20 percent benzocaine gels in patients with acute toothaches: Efficacy, tolerability and compliance with label dose administration directions,” *Journal of the American Dental Association*, vol. 144, no. 5, pp. 517–526, 2013.
7. F. R. Greer, M. Shannon, Committee on Nutrition, and Committee on Environmental Health, “Infant methemoglobinemia: the role of dietary nitrate in food and water,” *Pediatrics*, vol. 116, no. 3, pp. 784–786, 2005.
8. B. Mokhlesi, J. B. Leiken, P. Murray, and T. C. Corbridge, “Adult toxicology in critical care: part I: general approach to the intoxicated patient,” *Chest*, vol. 123, no. 2, pp. 577–592, 2003.
9. Stolbach and R. S. Hoffman, “Respiratory principles,” in *Goldfrank’s Toxicologic Emergencies*, L. S. Nelson, N. A. Lewin, M. A. Howland, R. S. Hoffman, L. R. Goldfrank, and N. E. Flomenbaum, Eds., chapter 21, pp. 308–310, McGraw-Hill, New York, NY, USA, 9th edition, 2011.
10. L. F. Rodriguez, L. M. Smolik, and A. J. Zbehlik, “Benzocaine induced methemoglobinemia: report of a severe reaction and review of the literature,” *Annals of Pharmacotherapy*, vol. 28, no.5, pp.643-649.1994.
11. Thomas M. Nappe, Anthony M. Pacelli, and Kenneth Katz An Atypical Case of Methemoglobinemia due to Self-Administered Benzocaine , Case Reports in Emergency Medicine Volume 2015.